Yisheng Pharmaceutical to Resume Production as Regulator Lifts Risk Control Measures

Yisheng Pharmaceutical Co., Ltd. (002566.SZ) announced it has received regulatory approval to resume production on previously halted lines after the Jilin Provincial Medical Products Administration lifted risk control measures.

Regulatory Action Lifted

In a company filing, Yisheng Pharmaceutical stated it received a "Notice of Lifting of Risk Control Measures" from the Jilin provincial regulator on September 21, 2026. The decision followed an on-site inspection which confirmed that safety hazards identified earlier had been eliminated.

With the measures now lifted, the company reported that the relevant production lines will begin an orderly resumption of operations. Yisheng plans to restore production according to its schedule to ensure market supply.

Background and Corrective Measures

The regulatory intervention began on July 1, 2026, when the company received a "Notice of Taking Risk Control Measures" from the same authority. The source did not specify the nature of the initial safety concerns.

Ad

In response, Yisheng Pharmaceutical said it immediately established a special task force to address the issues. The company undertook a series of corrective actions, including:

• Rectifying identified defects and investigating root causes.
• Improving and perfecting management systems.
• Strengthening personnel training.
• Addressing internal control weaknesses.

Company Outlook

Yisheng Pharmaceutical stated that the temporary production halt and subsequent resumption are not expected to have a major adverse impact on the company's current operating performance. This assessment provides key guidance for investors on the financial implications of the two-month regulatory issue.